advertisement

Topcon

Abstract #18000 Published in IGR 9-2

Nd:YAG laser iridotomy in the management of secondary glaucoma associated with Behçet's disease

Elgin U; Berker N; Batman A; Soykan E
European Journal of Ophthalmology 2007; 17: 191-195


PURPOSE: To report the outcome of Nd:YAG laser iridotomy in the management of secondary glaucoma associated with Behçet's disease (BD). METHODS: In this prospective study, Nd:YAG laser iridotomy was performed on eyes with secondary angle-closure and pupillary block glaucoma associated with BD. The pretreatment and post-treatment intraocular pressures (IOP) and the number of antiglaucoma medications were compared by Mann-Whitney U test. RESULTS: The study consisted of 16 eyes of 11 patients (2 female, 9 male, mean age 39.2 ± 8.9 years). Post-treatment follow-up ranged from 6 to 36 months (mean 13.8 ± 8.9). The mean IOP was 21.6 ± 2.5 mmHg on 2.5 ± 0.6 medications before iridotomy. IOP reduced to 17.7 ± 2.5 mmHg on 1 ± 0.6 medications at the first month and 17.1 ± 3.2 mmHg on 1.7 ± 0.9 medications at the sixth month of treatment. The differences between IOP and number of antiglaucoma medications at baseline and at the sixth month of the treatment was statistically significant (p < 0.00001). For four eyes trabeculectomy with mitomycin C and for one eye Ahmed valve implantation were performed in the follow-up period. CONCLUSIONS: Nd:YAG laser iridotomy can provide reduction of IOP and the number of antiglaucoma medications in selected cases with secondary glaucoma associated with Behcet's disease.

Dr. U. Elgin, Ankara Ulucanlar Eye Research Hospital, 06490 Bahcelievler, Ankara, Turkey. ufukelgin@superonline.com


Classification:

12.2 Laser iridotomy (Part of: 12 Surgical treatment)
9.4.6 Glaucomas associated with inflammation, uveitis (Part of: 9 Clinical forms of glaucomas > 9.4 Glaucomas associated with other ocular and systemic disorders)
9.3.1 Acute primary angle closure glaucoma (pupillary block) (Part of: 9 Clinical forms of glaucomas > 9.3 Primary angle closure glaucomas)



Issue 9-3

Change Issue


advertisement

Oculus